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This  report  describes  the  analytical  validation  and  application  of the homogeneous  mobility  shift  assay
(HMSA)  method  for the  measurement  of  adalimumab  and  human  antibodies-to-adalimumab  (ATA)  in
serum samples  from  patients  who  have  lost  response  to adalimumab  treatment.  Validation  of  the  ATA-
and the  adalimumab-HMSA  revealed  a  lower  limit  of detection  to  be 0.026  U/mL  for  ATA  and  0.018  g/mL
for  adalimumab  in  serum  samples.  Intra-assay  and  inter-assay  precision  determination  yielded  a coef-
ﬁcient  of variation  of less  than 15%,  and  the accuracy  of  both  assays  was  within  20%.  Adalimumab  drugdalimumab
nti-drug antibody
utoimmune diseases
herapeutic drug monitoring
mmunogenicity
tolerance  in  the  ATA-HMSA  was up to 20  g/mL  in the  test  serum.  Serum  samples  from  100  drug-naïve
healthy  subjects  were  tested  to  set-up  the  cut point  of  0.55  U/mL  for  ATA  and  0.68  g/mL  for  adalimumab.
Analysis  of  100  serum  samples  from  patients  who  were  losing  response  to adalimumab  showed  that  26%
had  an adalimumab  level  below  the cut  point,  of  these  68%  were  ATA  positive.  Overall,  44%  of  the patients
(44/100)  were  positive  for  ATA.  This  study  presents  evidence  that  drug  and  anti-drug  antibody  levels  are
of patobility shift assay important  determinants  
. Introduction
Many chronic inﬂammatory diseases are mediated by up-
egulation of the pro-inﬂammatory cytokine tumor necrosis
actor-alpha (TNF-)  [1].  The therapeutic use of anti-TNF-  antag-
nists such as inﬂiximab, adalimumab, and certolizumab pegol
as greatly improved the treatment of rheumatoid arthritis (RA),
soriasis (PS), and inﬂammatory bowel disease (IBD, Crohn’s dis-
ase and/or ulcerative colitis) [2].  The anti-TNF-  therapeutics are
ffective in reducing disease activity, and offer signiﬁcant bene-
ts in quality of life and may  have the potential to change the
rogression of the disease when given early [2,3]. However, over
0% of patients fail to respond to anti-TNF-  therapy, and approx-
mately 60% of patients who responded initially lose the response
ver time, and require either drug dose-escalation or switch to an
lternative agent in order to maintain response [4].  Anti-drug anti-
ody formation may  increase drug clearance in treated patients
nd/or neutralize the drug effect, thereby potentially contribut-
ng to the loss of response [5].  Anti-drug antibodies could also
ause adverse events such as serum sickness and hypersensitivity
Abbreviations: ATA, antibodies-to-adalimumab; CD, Crohn’s disease; HMSA,
omogenous mobility shift assay; IBD, inﬂammatory bowel disease; PS, psoriasis;
A,  rheumatoid arthritis; TNF-, tumor necrosis factor-alpha; UC, ulcerative colitis.
∗ Corresponding author. Tel.: +1 858 882 5983; fax: +1 858 410 0297.
E-mail address: ssingh@prometheuslabs.com (S. Singh).
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reactions [6,7]. Moreover, recent data suggest that the standard
dosing regimen for TNF--blocking drugs may  be suboptimal in
some IBD patients, and an individualized dosing regimen to achieve
therapeutic drug levels may  be needed in order to maximize the
initial drug response and to maintain remission [8].  Therefore,
accurate monitoring of serum drug and anti-drug antibody lev-
els should be an important part of therapy for patients being
treated with protein-based drugs. For this purpose, we  have pre-
viously developed and validated a novel homogeneous mobility
shift assay (HMSA) using size-exclusion high-performance liquid
chromatography (SE-HPLC) to quantitatively measure both inﬂix-
imab and antibody-to-inﬂiximab (ATI) in human serum [9]. The
HMSA method overcomes many limitations found in other meth-
ods, such as the bridging enzyme-linked immunosorbent assay
(ELISA) method [10] and the radioimmunoassay (RIA) method
[11]. The advantages of the HMSA method include high sensitiv-
ity, speciﬁcity, and accuracy and the ability to detect all isotypes of
immunoglobulin and subtypes of IgG such as IgG4. Using the HMSA
method, it is possible to measure ATI in the presence of high levels
of inﬂiximab drug in patient serum [9],  which is not possible with
the ELISA method.
Adalimumab (Humira®) is a fully humanized monoclonal anti-
body against TNF-, and is approved for the treatment of RA and
Open access under CC BY-NC-ND license.Crohn’s disease (CD) via subcutaneous injection. In the CLASSIC
I and II clinical trials, adalimumab treatment resulted in a sig-
niﬁcantly higher rate of remission of CD [12,13].  Even though it
is fully humanized, adalimumab does not eliminate the risk of
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mmunogenicity in both CD and RA patients [14,15]. Generation of
ntibodies-to-adalimumab (ATA) in the serum is associated with
ower serum adalimumab concentrations and reduced response
ate to treatment. In the present study, we evaluated the feasibility
f using the HMSA method for the measurement of adalimumab
nd ATA levels in patients who have lost response to adalimumab
herapy.
. Materials and methods
.1. Materials
Individual serum samples from healthy controls were obtained
rom blood bank donors (Golden West Biologics, Temecula, CA).
era from patients with RA, PS, and IBD treated with adalimumab
ere drawn according to a protocol approved by an Institu-
ional Review Board/Ethics Committee. Unless otherwise noted, all
eagents and chemicals were obtained from Thermo Fisher Scien-
iﬁc (Waltham, MA)  or Sigma Aldrich Corporation (St. Louis, MO).
.2. Preparation of reagents
.2.1. ATA calibration serum
ATA-positive sera were prepared by immunizing two rabbits
ith puriﬁed adalimumab (ProSci, Inc., San Diego, CA). Bleeds of
nti-adalimumab positive sera from the rabbits were pooled and
he relative amount of ATA was arbitrarily deﬁned as 100 U/mL,
qual to 1:100 dilutions. The pooled ATA calibration serum was
liquoted and stored at −70 ◦C.
.2.2. Conjugation of adalimumab and TNF-˛
The method for the conjugation of AlexaFluor-488 to adali-
umab  was same as described previously [9].  Brieﬂy, commercially
vailable adalimumab (Humira®, Abbott Laboratories, Abbott Park,
L) was buffer exchanged with phosphate buffered saline (PBS, pH
.3) and labeled with AlexaFluor-488 (Life Technology, Carlsbad,
A) following the manufacturer’s instructions. Only those conju-
ates containing 2–3 ﬂuorescent dyes per antibody qualiﬁed for
he ATA-HMSA. Conjugation of AlexaFluor-488 to TNF- was per-
ormed as described previously [9].
.3. HMSA for ATA and adalimumab
The procedure for the ATA-HMSA and the adalimumab-HMSA
ere similar to the ATI-HMSA as described previously [9],  except
hat AlexaFluor-488 labeled adalimumab was used in the ATA-
MSA. In brief, serum samples were ﬁrst acid dissociated with 0.5 M
itric acid (pH 3.0) for 1 h at RT, and then neutralized with 10× PBS
pH 7.3) in the presence of adalimumab-AlexaFluor-488 in a 96-
ell plate format. The plate was incubated for 1 h at RT on an orbital
haker to complete the formation of the immune complexes. The
quilibrated samples were ﬁltered through a MultiScreen-Mesh
ilter plate equipped with a Durapore membrane (0.22 m;  EMD
illipore, Billerica, MA)  into a 96-well receiver plate (Nunc, Thermo
isher Scientiﬁc, Waltham, MA). The recovered solutions were indi-
idually loaded into an HPLC system (Agilent Technologies 1200
eries HPLC system, Santa Clara, CA) equipped with a BioSep SEC-
000 column (Phenomenex, Torrance, CA). The chromatography
as run at the ﬂow-rate of 1 mL/min with 1× PBS (pH 7.3) as
he mobile phase for a total of 20 min, and was monitored with
 ﬂuorescence detector at excitation and emission wavelengths of
94 nm and 519 nm,  respectively. ChemStation Software (Agilent
echnologies, Santa Clara, CA) was used to set-up and collect data
rom the runs automatically and continuously.
To generate a standard curve, one aliquot of the stock ATA cali-
ration serum was thawed and diluted to 2% in volume with rabbitBiomedical Analysis 78– 79 (2013) 39– 44
serum (Sigma Aldrich, St. Louis, MO)  in HPLC assay buffer (1× PBS,
pH 7.3) to achieve ﬁnal concentrations in the assay wells of 0.031,
0.063, 0.125, 0.250, 0.500, 1.000, 2.000, and 4.000 U/mL. Three qual-
ity control (QC) samples were prepared by diluting the calibration
serum in assay buffer with 0.1% BSA to yield the high (1.600 U/mL),
mid  (0.600 U/mL), and low (0.200 U/mL) control concentrations.
Similarly, adalimumab calibration standards were prepared by seri-
ally diluting puriﬁed adalimumab with assay buffer containing 0.1%
BSA to achieve ﬁnal concentrations of 0.013, 0.025, 0.050, 0.100,
0.200, 0.400, 0.800 and 1.600 g/mL of adalimumab and ﬁnal NHS
concentration of 4% in the reaction mixture. Three adalimumab
QC samples were prepared by diluting the adalimumab calibra-
tion standard with assay buffer and 0.1% BSA to yield the high
(25 g/mL), mid  (10 g/mL), and low (5 g/mL) control concen-
trations.
2.4. ATA-HMSA and adalimumab-HMSA evaluation
The analytical validations including the performance character-
istics for the ATA-HMSA and the adalimumab-HMSA (calibration
standards, assay limits, assay precision [intra- and inter-assay],
linearity of dilution, and substance interference) were performed
based on the industrial recommendations [16]. A panel of serum
samples from drug-naïve healthy donors (n = 100; Golden West Bio-
logics. Temecula, CA) were analyzed to determine the assay cut
points for the ATA-HMSA and adalimumab-HMSA. The samples
were normally distributed and parametric statistics were applied
to determine the cut point. The assay cut points were deﬁned as
the threshold above which samples were deemed to be positive,
and was  set to have an upper negative limit of approximately 99%,
calculated by using the lowest mean value of individual samples
interpolated from the standard curve + 3.0x the standard deviation
(SD).
2.5. Data analysis
Data analysis was  performed with the use of a proprietary auto-
mated program run on R software (R Development Core Team,
Vienna, Austria) [9]. Brieﬂy, the R program opened the Chem-
Station ﬁles, normalized the spectra, determined the area under
each peak, and calculated the proportion of total peak areas
shifted to the bound ATA/adalimumab-AlexaFluor-488 complexes
over the total bound and free adalimumab-AlexaFluor-488 peak
areas in the ATA-HMSA. An exponential association standard curve
was generated from the standards and the measured ATA val-
ues were interpolated from the curve. To obtain the actual ATA
and adalimumab concentrations in the serum, the interpolated
results from the standard curves were multiplied by the dilution
factor.
3. Results and discussion
3.1. Evaluation of the ATA-HMSA and the adalimumab-HMSA
Because the maintenance protocol for patients treated with
adalimumab requires biweekly dosing, and the estimated half-life
of the drug in human blood is 15–20 days, the collection of a large
quantity of ATA-positive sera from patients for use as calibration
standards is a challenge. In theory, antisera from any mammalian
species will bind to and form immune complexes with adalimumab,
and show a similar SE-HPLC proﬁle when compared to human
immune complexes. Therefore, in order to produce a large quantity
of ATA-positive sera for calibration needs, two rabbits were immu-
nized with puriﬁed adalimumab and different bleeds of antisera
were pooled to serve as calibration standards. The relative amount
of ATA was  arbitrarily deﬁned as 100 U/mL, equal to 1:100 dilutions.
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Table  1
Characteristics of the ATA-HMSA and the adalimumab-HMSA standard curves.
ATA-HMSA Adalimumab-HMSA
ATA Standard
(U/mL)
Back calculated concentration
(mean, U/mL)
Error
(%)
CV
(%)
n Adalimumab Standard
(g/mL)
Back calculated concentration
(mean, g/mL)
Error
(%)
CV
(%)
n
4.000 3.820 4.51 0.47 29 1.600 0.973 39.17 0.31 29
2.000  2.099 4.94 4.87 29 0.800 0.898 12.21 4.89 29
1.000  0.970 3.03 7.76 29 0.400 0.405 1.35 10.36 29
0.500  0.496 0.71 9.31 29 0.200 0.192 3.94 13.41 29
0.250  0.263 5.16 10.45 29 0.100 0.104 4.12 16.09 29
0.125  0.132 5.58 15.8 29 0.050 0.055 9.39 18.92 29
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0.031  0.017 44.84 29.03 29 
hen serial dilutions of the ATA calibration standards were incu-
ated with adalimumab-AlexaFluor-488, dose-dependent immune
omplexes were formed with concomitant reduction of the free
dalimumab-AlexaFluor-488. Analyses were then conducted by
E-HPLC, in which the shifted peak area of the immune com-
lexes and free adalimumab-AlexaFluor-488 were calculated. The
tandard curve generated by plotting the proportion shifted area
s. ATA concentration is shown in Fig. 1A. The lowest concentra-
ion of ATA in the standard curve was 0.031 U/mL. The error for the
ack-calculated values of the 29 standard curve runs was  within
0%, except for the lowest concentration (0.031 U/mL) (Table 1).
he CV was <20% for concentrations above 0.031 U/mL, and the
ynamic range of the assay was two orders of magnitude. The
alculated limit of detection (LOD) was 0.026 U/mL from the 29
tandard curve runs based on the method described previously
9].  The calculated lower limit of quantitation (LLOQ) and upper
imit of quantitation (ULOQ) were 0.063 U/mL and 25.000 U/mL,
espectively. Complete analytical validation of the ATA-HMSA was
erformed with the high (1.600 U/mL), mid  (0.600 U/mL), and low
0.200 U/mL) QCs by multiple analysts using different instruments
n different days. As shown in Table 2A,  the ATA-HMSA intra-
ssay precision had a CV < 3% and an accuracy rate was <13%
rror. The inter-assay precision (run-to-run, analyst-to-analyst and
nstrument-to-instrument) had a CV of <9% and an accuracy of <18%
rror.
To evaluate the performance of the adalimumab-HMSA, puriﬁed
dalimumab was used as the calibration standard and AlexaFluor-
88 was used to label the TNF-. The performance characteristics
f the adalimumab-HMSA standard curve in the concentration
ange of 0.012–1.600 g/mL (Fig. 1B) was similarly assessed over
9 experimental runs by multiple analysts using different instru-
ents on different days (Table 1). The error for the back-calculated
alue of the 29 standard curve runs was within 15% except for
he highest and lowest concentrations (Table 1). The CV was <25%
xcept for the lowest concentration, and the dynamic range was
wo orders of magnitude. The calculated LOD, LLOQ, and ULOQ
or the adalimumab-HMSA were 0.018 g/mL, 0.040 g/mL, and
.100 g/mL, respectively. As shown in Table 2B,  the intra-assay
recision and accuracy for the adalimumab-HMSA were <20% and
able 2A
ssay precision of the ATA-HMSA.
Intra-assay precision (n = 10) Inter-assay precision
Run-to-run (n = 5)
High Mid  Low High Mid  
Expected (U/mL) 1.600 0.600 0.200 1.600 0.600 
Measured (mean, U/mL) 1.800 0.574 0.180 1.797 0.562 
SD  0.039 0.009 0.016 0.125 0.024 
CV  (%) 2.170 1.600 1.830 6.94 4.33 
Accuracy (%error) 12.530 4.410 10.250 12.33 6.41  0.026 2.46 24.93 29
 0.006 51.84 34.58 29
<3%, respectively, whereas the inter-assay precision and accuracy
for the adalimumab-HMSA were <12% and <22%, respectively.
To determine the linearity of dilution of both the ATA-HMSA
and the adalimumab-HMSA, human serum samples containing a
high titer of ATA or a high concentration of adalimumab were used.
The samples were diluted serially 2-fold within the linear range
of the standard curves and analyzed using the ATA-HMSA and the
adalimumab-HMSA, respectively. The observed values of ATA or
adalimumab were compared with the expected levels of ATA or
adalimumab in the serum samples. The R2 values for adalimumab
and ATA were 0.9933 and 0.9977, respectively. Assays had slopes of
0.9747 for adalimumab and 0.876 for ATA, demonstrating accurate
linear regression.
The effect of the potential interfering substances present in
the serum was also evaluated in both the ATA-HMSA and the
adalimumab-HMSA as described previously (Supplementary Table
1) [9].  TNF- and TNF- do not interfere with the assay at their
physiological levels of approximately 6.00 pg/mL. At concentra-
tions of greater than 100 ng/mL, TNF- begins to compete with the
TNF--AlexaFluor-488 substrate for binding to adalimumab. How-
ever, this is 1.56 × 104 fold higher than the typical physiological
levels seen in human sera. No signiﬁcant interference was observed
in the physiological levels of immunoglobulin, rheumatoid factor,
hemolyzed serum, and lipemic serum. In addition, the presence of
azathioprine up to 10 M and methotrexate up to 2.0 mM  did not
affect the assays (data not shown). Testing of interfering agents also
assists in demonstrating the speciﬁcity of the assay. In particular,
none of the immunoglobulins spiked into normal human serum
formed immunocomplexes with adalimumab-AlexaFluor-488 that
could be detected by the HPLC assay. Further, polyclonal anti-
adalimumab antibodies from the rabbit serum utilized for standard
curve generation were puriﬁed by Protein G afﬁnity chromatog-
raphy. These puriﬁed, IgG anti-adalimumab antibodies showed
speciﬁc, high afﬁnity binding to adalimumab-AlexaFluor-488 (data
not shown).
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jpba.2013.01.031.
Substantial concentrations of adalimumab may  be present in
the serum from patients, even if the blood is drawn at the trough
Analyst-to-analyst (n = 3) Instrument-to-instrument (n = 3)
Low High Mid Low High Mid  Low
0.200 1.600 0.600 0.200 1.600 0.600 0.200
0.176 1.689 0.532 0.169 1.708 0.526 0.166
0.012 0.142 0.040 0.011 0.123 0.031 0.010
6.96 8.420 7.450 6.530 7.190 5.950 5.970
12.12 5.590 11.250 15.560 6.750 12.370 17.180
42 S.-L. Wang et al. / Journal of Pharmaceutical and Biomedical Analysis 78– 79 (2013) 39– 44
Table 2B
Assay precision of the adalimumab-HMSA.
Intra-assay precision (n = 10) Inter-assay precision
Run-to-run (n = 5) Analyst-to-analyst (n = 3) Instrument-to-instrument (n = 3)
High Mid Low High Mid  Low High Mid  Low High Mid Low
Expected (g/mL) 1.000 0.400 0.200 1.000 0.400 0.200 1.000 0.400 0.200 1.000 0.400 0.200
Measured (mean, g/mL) 0.974 0.392 0.189 1.016 0.446 0.215 1.032 0.487 0.220 0.917 0.442 0.202
SD  0.017 0.075 0.019 0.052 0.052 
CV  (%) 1.700 19.200 1.700 5.060 11.700 
Accuracy (%error) 2.620 2.090 2.620 1.650 11.570 
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Fig. 1. The ATA-HMSA (A) and the adalimumab-HMSA (B) standard curves. Serial
dilutions of the ATA calibration standards (A) or adalimumab calibration standards
(B)  were incubated with adalimumab-AlexaFluor-488 or TNF--AlexaFluor-488,
respectively, which dose-dependently formed immune complexes. Immune com-
plexes and remaining free adalimumab-AlexaFluor-488 or TNF--AlexaFluor-488
were resolved by SE-HPLC analysis. An exponential association standard curve was
generated from the calibration standards. The means and standard deviations for
three replicate values for each point on the curve were plotted.0.021 0.043 0.024 0.013 0.056 0.007 0.010
9.680 4.170 4.820 5.990 6.120 1.650 4.920
7.430 3.140 21.670 10.200 8.270 10.540 1.270
time point due to the biweekly dosing regimen. As discussed pre-
viously, the presence of therapeutic antibody in the patient serum
signiﬁcantly affected the quantitative measurement of anti-drug
antibodies in the bridging ELISA assay. To address this issue in the
HMSA-based assays, ATA-positive human patient serum was tested
in the presence of up to 40 g/mL adalimumab to determine the
concentration at which adalimumab would interfere with the ATA
quantitation. When adalimumab was present in a sample, the total
ATA was  calculated using the equilibrium equation [9].  As shown
in Fig. 2, the ATA-HMSA could detect ATA levels as low as 10 U/mL
in serum samples containing 20 g/mL of adalimumab with 68.5%
recovery.
3.2. Cut point determinations for the ATA-HMSA and the
adalimumab-HMSA
We  screened 100 serum samples collected from adalimumab
drug-naïve healthy subjects to establish the cut points for the
ATA-HMSA and the adalimumab-HMSA. In the ATA-HMSA, the
proportion of shifted area over the total area was near the LOD,
and the mean value of the extrapolated ATA concentrations in
serum from the standard curve (multiplied by the dilution factor of
50) was  0.329 ± 0.073 U/mL. The calculated cut point for ATA was
0.549 U/mL (mean + 3.0x SD). There was only one sample that con-
tained ATA levels slightly higher than the cut point (0.630 U/mL),
which resulted in a clinical speciﬁcity of 99% (Fig. 3). The same
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Fig. 2. ATA-HMSA drug tolerance. Interference by adalimumab in the ATA-HMSA
was  assessed by increasing doses of adalimumab (1.25–40 g/mL) in each of the
three different ATA concentrations (10, 30, and 80 U/mL). ATA-HMSA could detect
an ATA level as low as 10 U/mL in the presence of up to 20 g/mL of adalimumab.
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Fig. 3. Plot of the proportion shifted area of donors used to derive the cutpoint
for ATA. 100 serum samples were collected from adalimumab drug-naïve healthy
subjects to establish the cut points for the ATA-HMSA and the adalimumab-HMSA.
T
c
l
m
H
3
f
o
o
o
m
s
c
2
f
t
i
a
t
d
t
p
2
p
s
s
m
w
b
a
m
w
p
w
w
c
b
t
m
d
b
A
0-0.68 0.69 -10.00 10.01-20.00 >20.00
0
10
20
30
40
50
60
70
80
90
100
Adali mumab (µg/mL)
A
T
A
 P
o
s
it
iv
it
y
 (
%
)
Adali mumab (µg/mL)
F
re
q
u
e
n
c
y
2 6 10 14 18 22 26 30 34 38 42 46 50
0
10
20
30
40
50A
B
Fig. 4. Histogram showing distribution of adalimumab levels in patients who  have
lost response to treatment (A) and relationship between adalimumab and ATA levelshe mean value of the extrapolated ATA concentrations in serum from the standard
urve (multiplied by the dilution factor of 50) was 0.329 ± 0.073 U/mL. The calcu-
ated cut point for ATA was 0.549 U/mL (mean + 3.0x SD).
ethod was applied to calculate the cut point for the adalimumab-
MSA: 0.676 g/mL, with a clinical speciﬁcity of 97%.
.3. Measurement of adalimumab and ATA in serum samples
rom patients treated with adalimumab
Recent scientiﬁc publications have reported that the incidence
f ATA in adalimumab-treated patients varies from 6% to 87% based
n different assay methods [13,15]. To evaluate the performance
f the adalimumab-HMSA and the ATA-HMSA in measuring adali-
umab  drug and ATA levels in patient serum, we collected serum
amples from 100 patients treated with adalimumab. The basic
haracteristics of the patients are shown in Supplementary Table
. All patients were treated with the adalimumab standard therapy
or at least 3 months. All patients initially responded to therapy but
hen lost the response based on evaluation of the disease activity
ndices for each indication. All samples were diluted 25-fold for the
dalimumab test and 50-fold for the ATA test. If the results of the
est were above the ULOQ, the samples were retested with further
ilutions in order to obtain accurate results. Of the 100 samples
ested for adalimumab, 26 samples had drug levels below the cut
oint of 0.68 g/mL, while 22 samples had the drug levels above
0 g/mL. The distribution of the adalimumab levels in these 100
atients is shown in Fig. 4A. The mean average ATA levels in the
tudied samples were 4.644 ± 19.203 U/mL (mean ± SD, n = 100),
igniﬁcantly higher than the healthy controls (0.329 ± 0.073 U/mL,
ean ± SD, n = 100, P < 0.00001). When the cut point of 0.55 U/mL
as applied to the ATA-HMSA test, 44 samples were determined to
e ATA positive (44%). There was an inverse relationship between
dalimumab concentration and ATA positivity. The lower the adali-
umab  concentration in the patient serum, the more ATA positivity
as detected. Sixty-eight percent of the serum samples were ATA
ositive when their adalimumab levels were below the cut point,
hile only 18.1% of the samples were ATA positive in patients
ith adalimumab levels >20 g/mL (Fig. 4B). There was no statisti-
ally signiﬁcant difference in ATA concentrations and ATA positivity
etween IBD, RA, and PS patient sera (Supplementary Fig. 1).
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jpba.2013.01.031.
Unfortunately, for patients who are losing response to adali-
umab  treatment, commercial assays are not yet available for the
etermination of adalimumab trough levels and anti-drug anti-
ody formation. Signiﬁcantly, the reported incidence of generating
TA in adalimumab-treated patients varies signiﬁcantly based onin  serum samples from patients treated with adalimumab (B). Higher frequency
was  observed in the lower adalimumab concentration range from patients who had
lost response to drug treatment (A). The relationship between ATA positivity and
adalimumab concentration was plotted (B).
different (non-commercial) assay methods [14,15,17,18].  The dis-
crepancies observed in these reports are likely due to different
assay technologies and the timing of blood drawn, as well as the
clinical assessments of patient conditions. Most of the available
assays for the assessment of anti-drug antibodies in serum are
based on solid phase enzyme immunoassay methodology (ELISA) or
derivatives thereof such as ECL. These assays differ signiﬁcantly in
clinical speciﬁcity and sensitivity with high risk of false-positives
due to non-speciﬁc binding to immunoglobulin from serum sub-
stances other than the drug [19]. Furthermore, these assays cannot
detect all the different forms of antibodies nor can they accu-
rately measure the free anti-drug antibodies if an excess of drug
is present in the serum [10]. RIA has also been developed to mea-
sure serum ATA and adalimumab concentrations and this assay has
shown some advantages over ELISA [20]. However, the inherent
RIA methodology is more cumbersome and commercially unavail-
able, and the use of radioactive materials is also a major drawback
in many clinical labs. The results presented here show that there
is higher incidence of ATA positivity (44%) in these secondary
non-responding patients compare to all patients treated with adali-
mumab  [15,17,21].  Twenty-six percent of the serum samples were
found to be adalimumab drug negative (below cut point), which
was unusual for patients under a biweekly dosing regimen. One of
the reasons to explain this ﬁnding could be ATA generation since
68% of these patients were found to be ATA positive. ATA may
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ncrease adalimumab clearance by forming immune complexes
hich are cleared by immunoglobulin Fc  receptors. ATA positivity
as signiﬁcantly lower (18.1%) when the adalimumab concentra-
ion in the serum was above 20 g/mL, and the loss of response to
dalimumab treatment in this patient population may  not neces-
arily be related to ATA formation. It is noteworthy that although
he homogeneous mobility shift assay is capable of detecting low
evels of ATA at very high concentrations of adalimumab, the sig-
iﬁcance of low levels of ATA in this patient population is currently
nknown. It has been proposed that switching to another class
f medication may  be beneﬁcial in this population subgroup of
atients [22].
. Conclusions
The ATA-HMSA and the adalimumab-HMSA are novel methods
or measuring ATA and adalimumab levels in patient serum sam-
les, and overcome many limitations encountered in solid-phase
LISA and RIA methods. The ATA-HMSA can be used to monitor anti-
rug antibody formation even in the presence of high serum drug
evels. Incorporation of routine measurement of anti-drug anti-
ody and drug levels in patients treated with protein therapeutics
s clinically useful and may  help to optimize patient management.
rospective randomized clinical studies in different chronic inﬂam-
atory diseases are being conducted to conﬁrm these current
ndings.
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